- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06386315
무통성 비호지킨 림프종 치료를 위한 저선량 방사선요법
무통성 비호지킨 림프종(POSEIDON)에 대한 저분할 방사선 요법(3Gy x 3분획): 다중 사이트 제2상 무작위 임상시험
This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.
연구 개요
상태
상세 설명
PRIMARY OBJECTIVE:
I. To show that the experimental arm [9 gray (Gy) in 3 fractions, 8 Gy in 2 fractions, or 10 Gy in 5 fractions] has significantly reduced acute toxicity (grade ≥ 2 adverse events at least possibly related to radiation treatment within 14 days after the end of radiation treatment [according to Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0] compared to 24 Gy in 12 fractions.
SECONDARY OBJECTIVES:
I. To evaluate patient reported quality of life. II. To evaluate response rate. III. To evaluate local control rate. IV. To evaluate relapse-free survival.
EXPLORATORY OBJECTIVES:
I. Financial toxicity will be assessed at the end of radiation treatment. II. Financial health care expenditure will be assessed at the end of radiation treatment III. Late toxicity.
CORRELATIVE RESEARCH OBJECTIVES:
I. Biopsies of enrolled patients will be evaluated for pathological assessment of cellular and genetic mutations to correlate them with disease local relapse and radiation resistance.
II. Patients will have their baseline positron emission tomography (PET)/computed tomography (CT) scan undergo auto-segmentation to calculate the functional imaging 18-fluoro-deoxyglucose (FDG) metabolic tumor volume (MTV), total lesions glycolysis (TLG) and maximum standardized uptake volume (SUVmax) of the sites to be treated with involved-site radiation therapy (ISRT) using MIMvista platform to correlate it with disease local relapse and treatment response.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo reduced dose ISRT once daily (QD) over 3, 2, or 5 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.
ARM II: Patients undergo standard of care (SOC) radiation therapy QD over 12 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.
After completion of study treatment, patients are followed up at days 7 and 14, months 3 and 6, and then every 6 months for up to 2 years post-radiation therapy.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
연구 장소
-
-
Arizona
-
Scottsdale, Arizona, 미국, 85259
- 모병
- Mayo Clinic in Arizona
-
연락하다:
- Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
-
수석 연구원:
- William G. Rule, MD
-
-
Florida
-
Jacksonville, Florida, 미국, 32224-9980
- 모병
- Mayo Clinic in Florida
-
연락하다:
- Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
-
수석 연구원:
- Brad S. Hoppe, MD, MPH
-
-
Minnesota
-
Albert Lea, Minnesota, 미국, 56007
- 모병
- Mayo Clinic Health System in Albert Lea
-
연락하다:
- Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
-
수석 연구원:
- John Yeakel, MD
-
Mankato, Minnesota, 미국, 56001
- 빼는
- Mayo Clinic Health System - Mankato
-
Rochester, Minnesota, 미국, 55905
- 모병
- Mayo Clinic in Rochester
-
연락하다:
- Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
-
수석 연구원:
- Scott C. Lester, MD
-
-
Wisconsin
-
Eau Claire, Wisconsin, 미국, 54701
- 모병
- Mayo Clinic Health System-Eau Claire Clinic
-
연락하다:
- Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
-
수석 연구원:
- Now Bahar Alam, MD
-
La Crosse, Wisconsin, 미국, 54601
- 모병
- Mayo Clinic Health System-Franciscan Healthcare
-
연락하다:
- Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
-
수석 연구원:
- Abigail L. Stockham, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Age ≥ 18 years
-
Histological confirmation of indolent B-cell lymphoma that can include any of the following:
- Follicular lymphoma (grade 1 or 2 or 3A)
- Marginal zone lymphoma (nodal or extranodal)
- Follicle center lymphoma
-
Any stage disease
-
Initial, refractory, or relapsed disease. If relapse involves the site to be treated there must be evidence of disease progression
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3
-
Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only
-
Provide written informed consent
-
Ability to complete questionnaire(s) by themselves or with assistance
-
Willing to return to enrolling institution for follow-up visits (during the active monitoring phase of the study). Virtual visits can also be considered as an option for applicable items
-
Confirmation from radiation oncologist of suitability to participate in study
Exclusion Criteria:
-
Any of the following:
- Pregnant women
- Nursing women
- Women of childbearing potential who are unwilling to employ adequate contraception
-
T-cell lymphoma
-
Receiving treatment for small and chronic lymphocytic lymphoma
-
Grade 3B follicular lymphoma
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: ARM 1 (reduced dose ISRT)
Patients undergo reduced dose ISRT once daily (excluding weekends): 9 Gy delivered in 3 treatment fractions or 8 Gy in 2 fractions. At physician discretion, patients may receive 10 Gy in 5 fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up. |
Ancillary studies Undergo CT or PET/CT
다른 이름들:
Undergo PET/CT
다른 이름들:
Undergo endoscopy
다른 이름들:
Undergo ISRT in 3 fractions
다른 이름들:
|
|
활성 비교기: ARM 2 (SOC ISRT)
Patients undergo standard of care (SOC) radiation therapy once daily (excluding weekends): 24 Gy in 12 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up. |
Ancillary studies Undergo CT or PET/CT
다른 이름들:
Undergo PET/CT
다른 이름들:
Undergo endoscopy
다른 이름들:
Undergo ISRT in 12 fractions
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of grade 2 or higher acute adverse events (AEs)
기간: Up to 14 days after radiation treatment
|
AEs will be graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Acute toxicity will be reported as a proportion calculated as the number of patients with acute toxicity divided by the total number of treatment patients. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2). |
Up to 14 days after radiation treatment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Response rate
기간: Up to 3 months after radiation treatment
|
Response rate will be defined as the proportion of patients displaying response (complete response or partial response) at 3 months post treatment. Complete response is defined as the disappearance of all signs of cancer in response to treatment. Partial response is defined decrease in the size of target lesions by ≥ 50%, with no increase in the size of any lesion and no appearance of new lesions. Treated patients who do not have a 3-month evaluation will be classified as a non-response. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2). |
Up to 3 months after radiation treatment
|
|
Time to progression rate
기간: Up to 24 months after radiation treatment
|
Local control will be defined as the number of days from end of radiation treatment until first local recurrence within 24 months post radiation treatment. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2). |
Up to 24 months after radiation treatment
|
|
Patient reported quality of life
기간: Up to 3 months after radiation treatment
|
Patient reported quality of life will be measured using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale, a 13-item questionnaire answered on a scale of 1-5 where 1=Not at all and 5=Very much. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2). |
Up to 3 months after radiation treatment
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Brad S. Hoppe, MD, MPH, Mayo Clinic
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- MC230808
- 23-010273 (기타 식별자: Mayo Clinic Institutional Review Board)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .